From Approval To Affordability: Biosimilar Regulation And Pricing In India And Australia

Abstract

Background: Biosimilars can improve access to biological medicines by increasing competition and reducing treatment expenditure. Their real-world impact depends on regulatory requirements, pricing policies, reimbursement arrangements, substitution practices, and market sustainability.

Objective: To compare the regulatory pathways, pricing and reimbursement mechanisms, market-access conditions, and selected approval-timing differences for biosimilars in India and Australia.

Methods: We conducted a structured comparative policy review using regulatory guidance, government documents, reimbursement materials, and peer-reviewed literature on biosimilars in both countries. We organised evidence by regulatory authority, legal framework, comparability requirements, clinical evidence, extrapolation, pharmacovigilance, pricing, reimbursement, substitution, and market access. An access–affordability–availability framework and a documentary SWOT analysis were used to synthesise the findings. Approval-year differences for selected trastuzumab and rituximab biosimilars were also examined descriptively.

Results: India and Australia apply broadly comparable scientific principles based on analytical, functional, non-clinical, and clinical comparability. However, India relies more strongly on domestic manufacturing, market competition, public procurement, and selective price regulation, whereas Australia uses a structured system linking TGA registration with PBS reimbursement, price management, and substitution policies. India’s major advantages include production capacity and competitive potential, while Australia demonstrates greater regulatory and reimbursement standardisation. The selected biosimilars showed earlier approval in India, although the observed intervals may reflect submission and commercial factors as well as regulatory processes.

Conclusion: Biosimilar access requires more than regulatory approval. Clear substitution principles, effective pharmacovigilance, sustainable pricing, supplier diversity, reimbursement, and reliable supply are essential for long-term affordability and availability in both countries....